Drug Profile
SYNSORB Pk
Alternative Names: SYNSORB Pk; TAK 751SLatest Information Update: 30 Jul 2003
Price :
$50
*
At a glance
- Originator SYNSORB Biotech
- Class Antibacterials
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Escherichia coli infections
Most Recent Events
- 19 Jan 2001 Phase-III clinical trials for Escherichia coli infections in USA (PO)
- 10 Jan 2001 SYNSORB Biotech has suspended further development of SYNSORB Pk® but the US NIH will continue their phase III trial on SYNSORB Pk® investigating a different clinical endpoint
- 10 Jan 2001 Suspended-III for Escherichia coli infections in Argentina (PO)